These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6431689)

  • 1. A process for preparation of 'high-purity' factor VIII by controlled pore glass treatment.
    Margolis J; Gallovich CM; Rhoades P
    Vox Sang; 1984; 46(6):341-8. PubMed ID: 6431689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of stable intermediate-purity factor VIII concentrate with a note on high-purity factor VIII.
    Margolis J; Rhoades P
    Vox Sang; 1979; 36(6):369-74. PubMed ID: 494575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled pore glass factor VIII concentrate: influence of heat treatment.
    Ockelford PA; Benny AG; Berry EW; Johns AS; Woodfield DG
    Pathology; 1987 Jan; 19(1):56-7. PubMed ID: 3108838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified glycine precipitation technique for the preparation of factor VIII concentrate of high purity and high stability.
    Brodniewicz-Proba T; Beauregard D
    Vox Sang; 1987; 52(1-2):10-4. PubMed ID: 3111087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A heat-treated factor VIII concentrate prepared by controlled-pore glass adsorption chromatography.
    Benny AG; Scott RH; Woodfield DG
    Transfusion; 1987; 27(2):174-7. PubMed ID: 3103269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A factor VIII concentrate of intermediate purity and higher potency.
    Smith JK; Evans DR; Stone V; Snape TJ
    Transfusion; 1979; 19(3):299-306. PubMed ID: 36691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods of preparing factor VIII. II. Preparation of a highly purified concentrate using CPG (controlled pore glass)].
    Perote P; Altamirano P; Aperador R; Camacho Y; Acosta J
    Sangre (Barc); 1984; 29(4-A):457-66. PubMed ID: 6438819
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor.
    Wickerhauser M; Mercer JE; Eckenrode JW
    Vox Sang; 1978; 35(1-2):18-31. PubMed ID: 664566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and small-scale production of a severely heated factor VIII concentrate.
    Knevelman A; de Wit HJ; Potstra P; vd Does JA
    Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of antihemophilic factor from indated plasma.
    Wickerhauser M
    Transfusion; 1976; 16(4):345-50. PubMed ID: 951729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factor VIII concentrate, highly purified and heated in solution (author's transl)].
    Heimburger N; Schwinn H; Gratz P; Lüben G; Kumpe G; Herchenhan B
    Arzneimittelforschung; 1981; 31(4):619-22. PubMed ID: 6788045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale preparation of a highly purified solvent-detergent treated factor VIII concentrate.
    Myers R; Wickerhauser M; Charamella L; Simon L; Nummy W; Brodniewicz-Proba T
    Vox Sang; 1991; 60(3):141-7. PubMed ID: 1907414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved method for the preparation of intermediate-purity antihemophilic factor concentrate for therapeutic usage.
    Liu DT; Irwin JF; LeFave RO; Grzenczyk B; Pai RC
    Vox Sang; 1980; 38(4):216-21. PubMed ID: 6774479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE; Smith JK
    Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate.
    Horowitz B; Lippin A; Chang MY; Shulman RW; Vandersande J; Stryker MH; Woods KR
    Transfusion; 1984; 24(4):357-62. PubMed ID: 6431661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale gel filtration chromatography for the production of a solvent/detergent-treated high-purity factor VIII concentrate.
    Dengler T; Stöcker U; Kellner S; Fürst G
    Vox Sang; 1990; 58(4):257-63. PubMed ID: 1697997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.